TABLE 1.

DHA pretreatment maintains the immature phenotype in LPS treated DC

		MED	DHA	LPS	LPS+DHA
MHCII	% of cells	17.6±0.6	4.2±1.2 #	31.6±2.2	7.24±1.5*
	MFI	192.1± 9.3	97.4±4.2 #	236.1±28.7	123.8±16.4*
CD40	% of cells	4.1±2.5	14.4±2.7 #	73.9±0.8	31.6±7.3 *
	MFI	163.2±9.7	105.4±7.8#	162.9±4.8	103.6±5.1*
CD80	% of cells	7.1±0.9	7.1±1.7	37±5.8	8.1±2.9 *
	MFI	72.8±0.4	103.2±2.1	128.8±7.1	79.6±4.4*
CD86	% of cells	3.8±1.1	8.5±2.7#	37.7±1.1	7.7±0.3 *
	MFI	82.2±0.2	64.5±4.0	88.3±1.3	60.4±2.9*
PD-L1	% of cells	94±0.6	95±0.3	98±0.3	94±0.1
	MFI	277.4±44.6	294.0±28.2	722.4±51.5	494.2±25.4*
PD-L2	% of cells	52±0.6	48±1.1	40±0.7	41±0.4
	MFI	48.1±0.9	39.2±3.4	56.5±1.7	43.8±8.8

Data are means ± SD, n=3. # indicates difference from medium control: p<0.05;

^*indicates difference from LPS treatment: p <0.01.

MED: medium control. Percentage of positive cells was based on isotype control.

CD11c+ DC (1×10⁶/ml) were cultured in the presence or absence of 50 µM of DHA for 24h, followed by treatment with 0.1µg of LPS for another 24h. Cells were incubated with various Abs for 30 min, and the expression of MHCII, CD40, CD80, CD86, PD-L1, PD-L2 was detected by flow cytometry.